RIGL Shares Outstanding History
Below is a table of the RIGL shares outstanding history going back to 2/23/2010:

Date RIGL Shares Outstanding
2/23/201051.97M
4/28/201051.97M
7/29/201052.13M
10/28/201052.15M
2/23/201152.27M
4/28/201152.29M
7/27/201171.22M
10/26/201171.24M
2/29/201271.44M
4/25/201271.45M
8/2/201271.63M
10/31/201287.00M
2/27/201387.14M
5/1/201387.14M
7/31/201387.43M
10/30/201387.43M
2/26/201487.52M
4/30/201487.53M
7/30/201487.79M
10/29/201487.79M
2/25/201588.04M
5/4/201588.14M
7/30/201588.50M
10/29/201588.53M
2/29/201690.56M
4/28/201692.14M
7/27/201694.59M
10/26/201698.94M
3/1/2017122.29M
4/26/2017122.43M
7/26/2017124.39M
11/1/2017146.49M
2/27/2018147.11M
3/26/2018147.37M
4/26/2018163.58M
8/2/2018166.44M
11/1/2018166.64M
2/21/2019167.17M
5/1/2019167.19M
8/1/2019167.61M
11/1/2019167.61M
2/20/2020168.57M
5/1/2020168.57M
8/1/2020168.93M
10/30/2020168.98M
2/23/2021170.04M
4/30/2021170.16M
7/30/2021170.85M
10/29/2021171.01M
2/24/2022171.68M
4/29/2022172.05M
7/29/2022172.84M

Also see: RIGL Market Cap History
RIGL YTD Return
RIGL Historical Shares Outstanding:
+10.15% CAGR
RIGL Historical Shares Outstanding: +10.15% CAGR

Mouse over chart for data details
2/23/2010 ...7/29/2022
Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Co.'s U.S. Food and Drug Administration approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the U.K. (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. We show 52 historical shares outstanding datapoints in our coverage of RIGL's shares outstanding history.

Understanding the changing numbers of RIGL shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like RIGL versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching RIGL by allowing them to research RIGL shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree RIGL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Rigel Pharmaceuticals (RIGL) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

RLAY Shares Outstanding History
RLMD Shares Outstanding History
RLYB Shares Outstanding History
RMD Shares Outstanding History
RMED Shares Outstanding History
RMTI Shares Outstanding History
RNA Shares Outstanding History
RNAZ Shares Outstanding History
RNXT Shares Outstanding History
RPHM Shares Outstanding History
More Healthcare companies »

 

RIGL Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.